全文获取类型
收费全文 | 4166篇 |
免费 | 329篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 213篇 |
妇产科学 | 76篇 |
基础医学 | 542篇 |
口腔科学 | 105篇 |
临床医学 | 447篇 |
内科学 | 1007篇 |
皮肤病学 | 53篇 |
神经病学 | 260篇 |
特种医学 | 405篇 |
外科学 | 363篇 |
综合类 | 65篇 |
一般理论 | 1篇 |
预防医学 | 468篇 |
眼科学 | 60篇 |
药学 | 279篇 |
1篇 | |
中国医学 | 2篇 |
肿瘤学 | 161篇 |
出版年
2022年 | 18篇 |
2021年 | 48篇 |
2020年 | 31篇 |
2019年 | 45篇 |
2018年 | 55篇 |
2017年 | 58篇 |
2016年 | 55篇 |
2015年 | 74篇 |
2014年 | 96篇 |
2013年 | 128篇 |
2012年 | 123篇 |
2011年 | 127篇 |
2010年 | 109篇 |
2009年 | 147篇 |
2008年 | 146篇 |
2007年 | 169篇 |
2006年 | 158篇 |
2005年 | 132篇 |
2004年 | 120篇 |
2003年 | 141篇 |
2002年 | 121篇 |
2001年 | 143篇 |
2000年 | 131篇 |
1999年 | 128篇 |
1998年 | 129篇 |
1997年 | 144篇 |
1996年 | 140篇 |
1995年 | 103篇 |
1994年 | 112篇 |
1993年 | 123篇 |
1992年 | 94篇 |
1991年 | 87篇 |
1990年 | 91篇 |
1989年 | 107篇 |
1988年 | 105篇 |
1987年 | 68篇 |
1986年 | 77篇 |
1985年 | 79篇 |
1984年 | 57篇 |
1983年 | 52篇 |
1982年 | 37篇 |
1981年 | 54篇 |
1980年 | 41篇 |
1979年 | 34篇 |
1978年 | 29篇 |
1977年 | 40篇 |
1976年 | 42篇 |
1975年 | 18篇 |
1974年 | 24篇 |
1973年 | 16篇 |
排序方式: 共有4526条查询结果,搜索用时 31 毫秒
111.
112.
113.
114.
115.
116.
Incomplete response to endoscopic sphincterotomy in patients with sphincter of Oddi dysfunction: evidence for a chronic pain disorder 总被引:4,自引:0,他引:4
Linder JD Klapow JC Linder SD Wilcox CM 《The American journal of gastroenterology》2003,98(8):1738-1743
OBJECTIVES: The efficacy of endoscopic treatment of sphincter of Oddi dysfunction (SOD) with endoscopic sphincterotomy (ES) remains controversial. Although some studies have shown a positive impact on patient symptoms after treatment, these reports have been largely qualitative and evaluated on short-term response. The aim of our study was to quantitatively measure the long-term outcomes of endoscopic therapy in patients with SOD. METHODS: Thirty-three patients with suspected SOD underwent selective sphincter of Oddi manometry (SOM) of the biliary and/or pancreatic sphincter. Each patient completed a telephone-based survey measuring symptomatic pain before and after SOM +/- ES. The questioner was blinded to the results of SOM. The patients with normal SOM or SOD but who did not undergo ES served as controls. RESULTS: Of these 33 patients (27 women, mean age 48.7 yr, range 13-74), 19 (57.5%) were found to have SOD (12 biliary, six pancreatic, one both). The average follow-up was 18.1 months (range 7-34). Of the patients with SOD, 17 (89%) underwent ES. At follow-up of the 19 patients undergoing ES, five were taking narcotics for persistent pain, two were taking antidepressants, and 15 identified the endoscopic therapy as the reason for their relief. Of the 14 controls, seven were taking narcotics, seven were taking antidepressants, and two identified the endoscopy as the reason for their relief; some patients were taking both antidepressants and narcotics. CONCLUSIONS: Patients found to have SOD who undergo ES are more likely to be improved on long-term follow-up when compared with patients with suspected SOD but normal manometry without ES. However, almost uniformly, despite ES, patients continue to have pain, which is consistent with most chronic pain disorders and which suggests a multifactorial cause for the pain. 相似文献
117.
Efficacy of the Za self-expandable metal stent for palliation of malignant biliary obstruction 总被引:3,自引:0,他引:3
Varadarajulu S Tutuian R Gostout C Kozarek R Wilcox CM Cotton PB 《Journal of clinical gastroenterology》2004,38(1):77-80
BACKGROUND: The efficacy and safety of the uncoated self-expandable Za metal stent for palliation of malignant distal biliary obstruction was prospectively analyzed. METHODS: Twenty-one patients with unresectable malignant tumors involving mid to distal common bile duct who presented with obstructive jaundice underwent endoscopic implantation of an uncoated self-expandable metal stent. Technical success with stent placement, adverse events, patient survival, duration of stent patency, and device performance were analyzed. RESULTS: Endoscopic biliary stenting was successful in all patients. No adverse events were encountered. The mean follow-up period of the 21 patients was 128 days (range, 3-263): 14 died of progressive disease at mean of 81 days (range, 3-210), 3 remain alive (at days 239, 250, and 263), and 4 were lost to follow-up (at days 90, 91, 92, and 116). The mean duration of stent patency was 249 days. Tumor ingrowth was observed in one patient (5%). Minor technical problems were encountered in 3 patients: 1 proximal deployment, 1 distal deployment, and difficulty associated with the delivery system in 1. CONCLUSIONS: The Za-metal stent provided effective palliation for patients with inoperable malignant biliary tumors. Although minor technical problems were encountered with stent deployment, the overall stent patency, efficacy, and safety profile appear satisfactory. 相似文献
118.
Familial protein S deficiency with a variant protein S molecule in plasma and platelets 总被引:3,自引:0,他引:3
A protein S deficient family presenting a variant protein S molecule in plasma and platelets is described. The propositus, age 20, and two brothers suffered from venous thrombotic disease. The propositus, the only family member studied while taking oral anticoagulants, had a protein S antigen (ag) level of 17% and undetectable activity. As demonstrated by immunoblotting both the propositus and one clinically affected brother (42% ag, 7% activity) presented variant protein S molecules of 65,000 molecular weight (mol wt) while the other clinically affected brother (64% ag, 11% activity) had only protein S with normal electrophoretic mobility of 70,000 mol wt. The mother had normal protein S levels (93% ag, 100% activity) but had both normal and variant protein S molecules and based on her functional protein S data a normal anticoagulant activity of the variant molecule is suggested. One asymptomatic but protein S deficient sister (68% ag, 9% activity) as well as the asymptomatic protein S deficient father (59% ag, 10% activity) had only protein S molecules of 70,000 mol wt. The variant protein S bound to C4b-binding protein in plasma, and differed from normal protein S in carbohydrate content. Platelets of each family member contained the same immunoblotting pattern of normal and variant protein S forms as found in plasma, consistent with the hypothesis that protein S gene expression involves codominant expression of two alleles that is similar in cells that control the synthesis of both platelet and plasma forms of protein S. 相似文献
119.
Crosslinking the CD27 antigen on T cells provides a costimulatory signal that, in concert with T-cell receptor crosslinking, can induce T- cell proliferation and cellular immune activation. We find that chronic lymphocytic leukemia (CLL) B cells from most patients coexpress both membrane-bound and soluble CD27, along with its newly identified ligand, CD70. The expression of soluble CD27 may preclude leukemic B cells from stimulating T cells via CD70, thereby potentially impairing their ability to function as effective antigen-presenting cells. We find that leukemic B-cell expression of soluble and membrane-bound CD27 can be downmodulated through a CD40-dependent signal. This signal also induces enhanced expression of CD70 on both normal and leukemic B cells. We find that tumor necrosis factor (TNF)-alpha, or the Th1 cytokine interferon (IFN)-gamma, also can induce downmodulation of CD27, whereas Th2-associated cytokines interleukin-4 (IL-4) or IL-10 can enhance leukemic B-cell expression of this accessory molecule. The modulation of CD27 induced by these conditions is accompanied by reciprocal changes in the expression levels of CD70, suggesting that these accessory molecules may be engaged in reciprocal receptor-ligand downmodulation. Consistent with this, we observe that co-culture of CLL B cells with transfected murine plasmacytoma cells that express human CD70 affects downmodulation of CD27 and enhanced expression of CD70 on leukemic B cells, but does not affect expression of CD27 mRNA. However, we find that CD40-crosslinking, in addition to reducing the level of CD27 protein, also reduces leukemic B-cell expression of CD27 mRNA. This argues that the changes in the expression levels of CD27 following CD40-signaling are not simply due to induced increases in the expression levels of CD70. Finally, we demonstrate that reciprocal changes in expression of CD27 and CD70 may contribute to the enhanced antigen-presenting capacity of CLL B cells after CD40-dependent leukemic B-cell activation. These findings expand the understanding of the regulation of costimulatory molecules important in antigen presentation and also have implications for the immunobiology of and therapy for CLL. 相似文献
120.
Douglas M. Simon John P. Cello Jorge Valenzuela Richard Levy Gordon Dickerson Richard Goodgame Michael Brown Kip Lyche W.Jeffrey Fessel James Grendell C.Mel Wilcox Nezam Afdhal Ronald Fogel Vonda Reeves-Darby John Stern Owen Smith Frank Graziano Douglas Pleakow Timothy Flanigan Timothy Schubert Mark Loveless Larry Eron Paul Basuk Maurizio Bonacini Jan Orenstein 《Gastroenterology》1995,108(6):1753-1760
Diarrhea is a significant problem in patients with acquired immunodeficiency syndrome (AIDS). The aim of this study was to determine octreotide effectiveness in refractory AIDS-associated diarrhea. In a 3-week protocol, 129 patients with a stool weight of >500 g/day despite standard antidiarrheal therapy were randomized to receive octreotide or placebo (3:2 ratio). Octreotide dose was increased 100 μg weekly to a maximum of 300 μg three times a day based on weekly 72-hour stool collections. Subsequently, patients received open-label octreotide at doses of up to 500 μg three times a day. A 30% decrease in stool weight defined response. After 3 weeks, 48% of octreotide- and 39% of placebo-treated patients had responded (P = 0.43). At 300 μg three times a day, 50% of octreotide- and 30.1% of placebo-treated patients responded (P = 0.12). At a baseline stool weight of 1000–2000 g/day, 57% of octreotide- and 25% of placebo-treated patients responded (P = 0.06). Response rates based on CD4 counts, diarrhea duration, body weight, human immunodeficiency virus risk factor, and presence or absence of pathogens showed no benefit of octreotide. Adverse events were more frequent in the octreotide-treated group. In the doses studied, octreotide was not more effective than placebo in patients with refractory AIDS-associated diarrhea. This lack of effectiveness may be attributable to inadequate sample size, doses, and duration of study treatment. 相似文献